Roger Mouawad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roger Mouawad has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
D. Khayat
15 shared publications- Claude Soubrane
AP-HP, Salpetriere Hospital, Paris, France
10 shared publications D Khayat
6 shared publicationsJ. Spano
5 shared publicationsO Rixe
5 shared publicationsO. Rixe
Salpetriere Hosp, Paris, France; Pfizer, Sandwich, United Kingdom; G. E. M. S., Buc, France; Scanner Alesia, Paris, France
5 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S223
1557 Impact of art therapy on the quality of life of cancer patients: The Salpetriere hospital experience
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S223
1557 Impact of art therapy on the quality of life of cancer patients: The Salpetriere hospital experience
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S347-S348
2057 Assessment oftumor-infiltrating lymphocytes in metastatic colorectal cancer patients treated by Bevacizumab-based chemotherapy
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S347-S348
2057 Assessment oftumor-infiltrating lymphocytes in metastatic colorectal cancer patients treated by Bevacizumab-based chemotherapy
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S693
3415 Soft tissue sarcomas of the great vessels are rare entities: A retrospective analysis of 20 patients
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S693
3415 Soft tissue sarcomas of the great vessels are rare entities: A retrospective analysis of 20 patients
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e19699
Age-related changes in plasma levels of inflamatory and angiogenic cytokins in patients with cancer.
E19699 Background: The majority of cancer incidence and mortality occurs in individuals aged older than 65 years, and the number of older adults with cancer is projected to significantly increase. As such, understanding the changes accompanying age in the context of the cancer patient is of critical importance. Age-related changes can impact tolerance of anticancer therapy and can shift the overall risk-benefit ratio of such treatment. It is increasingly recognized that several laboratory markers may predict morbidity and mortality in older adults; these biologic variables may further aid in stratifying this group of patients based on risk. In this study we evaluated. In this study we examine inflammatory and angiogenic markers in cancer patients classified according to there age in older adults. Methods: Using ELISA test circulating Il-6, TNF alpha and vegf were measured in the sera of 80 patients with different cancer of whom 38 (48%) were female in comparison to 40 healthy controls.Three groups of patients were studied, the first consisted of 25 patients (age 30-40 years); the second of 25 (age 40-70 years), the third group of 30 elderly persons (>70 years). Results: Serum IL-6 and VEGF levels were higher in cancer patients as compared to control group.serum IL-6, TNF alpha and VEGF levels were higher in cancer patients as compared to control group. When patients were classified according to their age, a significant age-related increase of IL-6 and VEGF were observed (p=0.009 and 0.034 respectively) but not with TNF alpha. Furthermore, high IL-6 and VEGF level were associated with further functional adverse outcomes. Conclusions: A specific inflamatory and angiogenic status exist for elderly patients. the increased level of these markers might predispose these patients to clinical manifestations and non tolerence of the treatment. However, a study comparing these parameters only in elderly patients (> 70 years) and relation to there clinical status are necesseary to confirme these results.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e19699
Age-related changes in plasma levels of inflamatory and angiogenic cytokins in patients with cancer.
E19699 Background: The majority of cancer incidence and mortality occurs in individuals aged older than 65 years, and the number of older adults with cancer is projected to significantly increase. As such, understanding the changes accompanying age in the context of the cancer patient is of critical importance. Age-related changes can impact tolerance of anticancer therapy and can shift the overall risk-benefit ratio of such treatment. It is increasingly recognized that several laboratory markers may predict morbidity and mortality in older adults; these biologic variables may further aid in stratifying this group of patients based on risk. In this study we evaluated. In this study we examine inflammatory and angiogenic markers in cancer patients classified according to there age in older adults. Methods: Using ELISA test circulating Il-6, TNF alpha and vegf were measured in the sera of 80 patients with different cancer of whom 38 (48%) were female in comparison to 40 healthy controls.Three groups of patients were studied, the first consisted of 25 patients (age 30-40 years); the second of 25 (age 40-70 years), the third group of 30 elderly persons (>70 years). Results: Serum IL-6 and VEGF levels were higher in cancer patients as compared to control group.serum IL-6, TNF alpha and VEGF levels were higher in cancer patients as compared to control group. When patients were classified according to their age, a significant age-related increase of IL-6 and VEGF were observed (p=0.009 and 0.034 respectively) but not with TNF alpha. Furthermore, high IL-6 and VEGF level were associated with further functional adverse outcomes. Conclusions: A specific inflamatory and angiogenic status exist for elderly patients. the increased level of these markers might predispose these patients to clinical manifestations and non tolerence of the treatment. However, a study comparing these parameters only in elderly patients (> 70 years) and relation to there clinical status are necesseary to confirme these results.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 8582
Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma: Relationships to clinicopathological parameters and tumor burden.
8582 Background:Melanoma metastasizes by either direct invasion of surrounding tissue or spreading through the lymphatic or vascular system. Recent studies have shown that Tie-2 receptor, can bind its agonistic ligand Angiopoietin-2, resulting in vessel destabilization and the resulting signaling pathway promotes angiogenesis. We previously showed that Serum Ang-2 was elevated in metastatic malignant melanoma patients. The aim of this study was to evaluate the presence of circulating Tie-2 and to assess a possible involvement of the Tie-2/Ang-2 axis, in tumor progression in metastatic malignant melanoma patients (MMM). Methods:Using ELISA assays, circulating Tie-2 and Ang-2 levels were measured in the sera of 90 patients with stage IV metastatic melanoma in comparison to 50 healthy controls Results: pretreatment circulating levels of sTie2 and Ang-2 were significantly elevated in melanoma patients as compared to healthy ones (median 3.99 vs 2.88 ng/ml, P=0.014 and 4856 vs 2225 pg/ml, P<0.001 respectively). None of the studied markers correlated with gender, age or LDH levels. The ratio of sTie-2/Ang-2 was significantly elevated in patients compared to controls (0.25 vs 0.044, P<0.001) and a positive correlation between sTie-2 and Ang-2 was observed (r’=0.430, p=0.0014). Tumor burden, i.e. number of metastatic sites was statistically associated with Tie-2 (p=0.033) but not Ang-2 levels. Serum Ang-2 levels were significantly elevated in patients with distant metastases compared with those without metastasis (median 5279 vs 3260 pg/ml, P= 0.01). However, sTie-2/Ang-2 ratio showed a relationship with metastasis. Conclusions: We showed that, serum Tie-2 and its ligand Ang-2 are elevated in metastatic malignant melanoma patients and as Tie-2/Ang-2 axes showed a relation with metastasis. Further studies are necessary to confirm these results and to determine whether Tie-2/Ang-2 axes can play a role as a prognostic tool or a target for therapeutic intervention.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 8582
Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma: Relationships to clinicopathological parameters and tumor burden.
8582 Background:Melanoma metastasizes by either direct invasion of surrounding tissue or spreading through the lymphatic or vascular system. Recent studies have shown that Tie-2 receptor, can bind its agonistic ligand Angiopoietin-2, resulting in vessel destabilization and the resulting signaling pathway promotes angiogenesis. We previously showed that Serum Ang-2 was elevated in metastatic malignant melanoma patients. The aim of this study was to evaluate the presence of circulating Tie-2 and to assess a possible involvement of the Tie-2/Ang-2 axis, in tumor progression in metastatic malignant melanoma patients (MMM). Methods:Using ELISA assays, circulating Tie-2 and Ang-2 levels were measured in the sera of 90 patients with stage IV metastatic melanoma in comparison to 50 healthy controls Results: pretreatment circulating levels of sTie2 and Ang-2 were significantly elevated in melanoma patients as compared to healthy ones (median 3.99 vs 2.88 ng/ml, P=0.014 and 4856 vs 2225 pg/ml, P<0.001 respectively). None of the studied markers correlated with gender, age or LDH levels. The ratio of sTie-2/Ang-2 was significantly elevated in patients compared to controls (0.25 vs 0.044, P<0.001) and a positive correlation between sTie-2 and Ang-2 was observed (r’=0.430, p=0.0014). Tumor burden, i.e. number of metastatic sites was statistically associated with Tie-2 (p=0.033) but not Ang-2 levels. Serum Ang-2 levels were significantly elevated in patients with distant metastases compared with those without metastasis (median 5279 vs 3260 pg/ml, P= 0.01). However, sTie-2/Ang-2 ratio showed a relationship with metastasis. Conclusions: We showed that, serum Tie-2 and its ligand Ang-2 are elevated in metastatic malignant melanoma patients and as Tie-2/Ang-2 axes showed a relation with metastasis. Further studies are necessary to confirm these results and to determine whether Tie-2/Ang-2 axes can play a role as a prognostic tool or a target for therapeutic intervention.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e16011
Potential activity and safety of gemcitabine and oxaliplatin (GEMOX) in different histologic subtypes of advanced thyroid cancer.
E16011 Background: Patients with advanced, incurable thyroid cancer have few satisfactory therapeutic options. In this present study we assessed the activity and safety of the association of gemcitabine and oxaliplatin (gemox) in patients with different histology of advanced thyroid cancer refractory to I-131 treatment. Methods: Twelve patients with advanced thyroid cancer (4 papillary, 6 vesicular, and 2 mixed) were evaluated from our specialized hospital. All were refractory to I-131 treatment with a median age of 64 years. All patients received a combination of gemcitabine (1,000 mg/m2) + oxaliplatin (100 mg/m2) every two weeks until progression, limiting toxicity or a plained stop at 12 cycles. The response was evaluated by Response Evaluation Criteria in Solid Tumors after 4 cycles. Results: At this time, twelve patients were evaluated over our series. Complete and partial responses were observed in 1 and 5 patients respectively, yielding an ORR of 50%. Stable disease was reported in another 4 patients (33%). Objective responses were noted in 83 % (5 out of 6) vesicular subtypes. This combination was generally well tolerated, no grade IV toxicity was observed. The most common treatment-related adverse event being asthenia (n = 10 with 3 grade III), peripheral neuropathy (n=11 with 1 grade III), diarrhea (n=1), anemia (n=12), thrombopenia (n=5), neutropenia (n=4 with 1grade III). There was no toxic death related to the treatment. Conclusions: The GEMOX regimen remains effective and well tolerated in advanced differentiated thyroid cancer. thus, further evaluation of this new combination seems warranted and will be presented. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e16011
Potential activity and safety of gemcitabine and oxaliplatin (GEMOX) in different histologic subtypes of advanced thyroid cancer.
E16011 Background: Patients with advanced, incurable thyroid cancer have few satisfactory therapeutic options. In this present study we assessed the activity and safety of the association of gemcitabine and oxaliplatin (gemox) in patients with different histology of advanced thyroid cancer refractory to I-131 treatment. Methods: Twelve patients with advanced thyroid cancer (4 papillary, 6 vesicular, and 2 mixed) were evaluated from our specialized hospital. All were refractory to I-131 treatment with a median age of 64 years. All patients received a combination of gemcitabine (1,000 mg/m2) + oxaliplatin (100 mg/m2) every two weeks until progression, limiting toxicity or a plained stop at 12 cycles. The response was evaluated by Response Evaluation Criteria in Solid Tumors after 4 cycles. Results: At this time, twelve patients were evaluated over our series. Complete and partial responses were observed in 1 and 5 patients respectively, yielding an ORR of 50%. Stable disease was reported in another 4 patients (33%). Objective responses were noted in 83 % (5 out of 6) vesicular subtypes. This combination was generally well tolerated, no grade IV toxicity was observed. The most common treatment-related adverse event being asthenia (n = 10 with 3 grade III), peripheral neuropathy (n=11 with 1 grade III), diarrhea (n=1), anemia (n=12), thrombopenia (n=5), neutropenia (n=4 with 1grade III). There was no toxic death related to the treatment. Conclusions: The GEMOX regimen remains effective and well tolerated in advanced differentiated thyroid cancer. thus, further evaluation of this new combination seems warranted and will be presented. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8522
Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.
8522 Background: Angiogenesis is an essential process in the development and growth of tumors. There are a large number of angiogenic mediators including the angiopoietin (Ang) family which acts in association with the vascular endothelial growth factor system to control vessel assembly during tumor progression. Therefore, these factors have been suggested as diagnostic and in some studies as prognostic tumor markers. The purpose of the present study was to evaluate the potential role of circulating soluble Ang-1 and 2 in metastatic malignant melanoma patients and their usefulness as markers in this pathology. Methods: Using a sensitive enzyme-linked immunosorbent assays, circulating Ang-1 and Ang-2 levels were measured in the sera of 67 patients with histologically proven stage IV metastatic melanoma treated by biochemotherapy; 23 had regional lymph node metastasis and 44 patients had distant organ metastasis. Results: Serum Ang-2 levels were significantly elevated in patients compared to controls (median 4,856 vs. 2,225 pg/mL, p < 0.001), there was no significant difference in Ang-1 levels, while the ratio of Ang-2/Ang-1 was significantly elevated in patients compared to controls (0.13 vs. 0.066, p < 0.001). Circulating Ang-1 level was higher in men than in women (p = 0.031). Patient's age, Breslow's classifications or LDH levels were not associated with serum angiopoetin levels. Serum Ang-2 levels were significantly elevated in patients with distant metastases compared with those without metastasis (median 5,080 vs. 3,360 pg/mL, p = 0.01). Tumour burden i.e. number of metastatic sites were not statistically significantly associated with Ang-2 levels. But, only patients with lymph node metastases (n = 23) had significantly lower levels than the 44 patients withmetastases at other sites (mean 3,250 vs. 4,458 pg/mL, p = 0.028). Time to disease progression was worse in patients with elevated Ang-2 levels (p = 0.04). Conclusions: Serum Ang-2 but not Ang-1 is elevated in metastatic malignant melanoma patients. Ang-2 may be a useful serum marker for monitoring of melanoma patients. In addition, it may be a promising therapeutic target for melanoma. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8522
Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.
8522 Background: Angiogenesis is an essential process in the development and growth of tumors. There are a large number of angiogenic mediators including the angiopoietin (Ang) family which acts in association with the vascular endothelial growth factor system to control vessel assembly during tumor progression. Therefore, these factors have been suggested as diagnostic and in some studies as prognostic tumor markers. The purpose of the present study was to evaluate the potential role of circulating soluble Ang-1 and 2 in metastatic malignant melanoma patients and their usefulness as markers in this pathology. Methods: Using a sensitive enzyme-linked immunosorbent assays, circulating Ang-1 and Ang-2 levels were measured in the sera of 67 patients with histologically proven stage IV metastatic melanoma treated by biochemotherapy; 23 had regional lymph node metastasis and 44 patients had distant organ metastasis. Results: Serum Ang-2 levels were significantly elevated in patients compared to controls (median 4,856 vs. 2,225 pg/mL, p < 0.001), there was no significant difference in Ang-1 levels, while the ratio of Ang-2/Ang-1 was significantly elevated in patients compared to controls (0.13 vs. 0.066, p < 0.001). Circulating Ang-1 level was higher in men than in women (p = 0.031). Patient's age, Breslow's classifications or LDH levels were not associated with serum angiopoetin levels. Serum Ang-2 levels were significantly elevated in patients with distant metastases compared with those without metastasis (median 5,080 vs. 3,360 pg/mL, p = 0.01). Tumour burden i.e. number of metastatic sites were not statistically significantly associated with Ang-2 levels. But, only patients with lymph node metastases (n = 23) had significantly lower levels than the 44 patients withmetastases at other sites (mean 3,250 vs. 4,458 pg/mL, p = 0.028). Time to disease progression was worse in patients with elevated Ang-2 levels (p = 0.04). Conclusions: Serum Ang-2 but not Ang-1 is elevated in metastatic malignant melanoma patients. Ang-2 may be a useful serum marker for monitoring of melanoma patients. In addition, it may be a promising therapeutic target for melanoma. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 9074
Flt-4 and its ligand VEGF-C in metastatic malignant melanoma: Relationships to clinicopathological parameters response and survival
9074 Background: Melanoma metastasizes by either direct invasion of surrounding tissue or spreading through the lymphatic or vascular system. Despite their clinical relevance, the mechanisms that guide the way of spreading and localization of metastases in different tissues are not well known. Recent studies have shown that Flt-4, a VEGF receptor, is activated by its ligand, VEGF-C. The resultant signaling pathway promotes angiogenesis and/or lymphangiogenesis. The aim of this study is to assess a possible involvement of the VEGF-C/Flt-4 axis, in lymphoangioginesis and tumor progression in metastatic malignant melanoma patients (MMM). Methods: Using ELISA assays, Flt-4 and VEGFC were measured in sera of 90 patients with MMM in comparison to 40 healthy controls. Flat-4&VEGF-C expressions on melanoma tumor were evaluated by immunohistochemical study. Survivals (DFS and OS) were analyzed using the Kaplan-Meier method. Results: Pretreatment median levels of sFlt-4 and sVEGF-C were significantly higher in MMM patients as compared to healthy ones (p=0.005, p<0.00001). A high expression of Flt-4 and VEGF-C in melanoma tumor was observed. None of the studied markers correlated with gender, age or LDH levels. An inverse correlation between Flt-4 expression & its soluble form was noted (r=-0.33 p=0.040). A positive correlation between sVEGF-C & sFlat-4 was observed (r’=0.430, p=0.0014). Furthermore, high expression & levels of sVEGF-C, sFlat-4 correlated to high tumor burden (p=0.02, p=0.045). Only sVEGFC/sFlat-4 ratio showed a relationship with lymph node metastasis. Pretreatment sFlat-4 level was significantly different (p=0.0125) between R (n=45) & NR patients (n=35) but not sVEGF-C level. After treatment, no change in the median sFlat-4 level was observed. By contrast, sVEGF-C increased specifically in NR patients with high tumor burden. Only elevated level of sFlat-4 concentration exert a significantly unfavorable impact on disease free survival (Χ2= 3,855, p=0.045). Conclusions: Our results suggest that, in MMM patients, the VEGF-C/Flt-4 axis enhances cancer cell invasiveness, contributes to the promotion of cancer cell metastasis and may prospectively identify high-risk patients with a worse prognosis. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 9074
Flt-4 and its ligand VEGF-C in metastatic malignant melanoma: Relationships to clinicopathological parameters response and survival
9074 Background: Melanoma metastasizes by either direct invasion of surrounding tissue or spreading through the lymphatic or vascular system. Despite their clinical relevance, the mechanisms that guide the way of spreading and localization of metastases in different tissues are not well known. Recent studies have shown that Flt-4, a VEGF receptor, is activated by its ligand, VEGF-C. The resultant signaling pathway promotes angiogenesis and/or lymphangiogenesis. The aim of this study is to assess a possible involvement of the VEGF-C/Flt-4 axis, in lymphoangioginesis and tumor progression in metastatic malignant melanoma patients (MMM). Methods: Using ELISA assays, Flt-4 and VEGFC were measured in sera of 90 patients with MMM in comparison to 40 healthy controls. Flat-4&VEGF-C expressions on melanoma tumor were evaluated by immunohistochemical study. Survivals (DFS and OS) were analyzed using the Kaplan-Meier method. Results: Pretreatment median levels of sFlt-4 and sVEGF-C were significantly higher in MMM patients as compared to healthy ones (p=0.005, p<0.00001). A high expression of Flt-4 and VEGF-C in melanoma tumor was observed. None of the studied markers correlated with gender, age or LDH levels. An inverse correlation between Flt-4 expression & its soluble form was noted (r=-0.33 p=0.040). A positive correlation between sVEGF-C & sFlat-4 was observed (r’=0.430, p=0.0014). Furthermore, high expression & levels of sVEGF-C, sFlat-4 correlated to high tumor burden (p=0.02, p=0.045). Only sVEGFC/sFlat-4 ratio showed a relationship with lymph node metastasis. Pretreatment sFlat-4 level was significantly different (p=0.0125) between R (n=45) & NR patients (n=35) but not sVEGF-C level. After treatment, no change in the median sFlat-4 level was observed. By contrast, sVEGF-C increased specifically in NR patients with high tumor burden. Only elevated level of sFlat-4 concentration exert a significantly unfavorable impact on disease free survival (Χ2= 3,855, p=0.045). Conclusions: Our results suggest that, in MMM patients, the VEGF-C/Flt-4 axis enhances cancer cell invasiveness, contributes to the promotion of cancer cell metastasis and may prospectively identify high-risk patients with a worse prognosis. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 3548
CT perfusion as index of activity of antiangiogenic treatment of metastatic carcinoma
3548 Background: the aim of this study was to evaluate the different Computed Tomography (CT) parameters, characterizing tissue perfusion by contrast medium in metastatis to define their relation with activity of an antiangiogenic compound, targeting the VEGF receptors 1 and 2, using this qualitative and quantitative method. Methods: 113 patients with metastatic renal cell, pancreatic, colonic carcinoma and melanoma treated with antiangiogenic compound, were studied by dynamic CT (64 slices, GE) : calculation of time to peak (TTP), positive enhancement integral (PEI), maximum slope of increase (MSI), maximum slope of decrease (MSD), blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface (PS) were performed. Value distributions in the normal and neoplastic wall, their variation after antiangiogenic therapies and their relation to mono and bidimensionnal or volume measurement and pathological vessel density (MVD) were evaluated. Results: BF, TTP, and especially PEI and PS were highter in tumor than in normal liver, respectively in 68, 76, 100 and 100%; PS was > 20 ml/min/100g in 100% of patients. PEI and PS decrease in 78% and 82% of patients submitted to antiangiogenic treatment at the first course. Decreased tumor perfusion (TP) was observed in patients responding to therapy, including liver metastasis. Furthermore, in 40 out of 60 patients with stable or progressive disease by RECIST, decreased TP was strongly correlated with clinical improvement. Significant correlation between PEI in tumor/PEI in the aorta and PS was found (R=0,679). Conclusion: CT perfusion could be reliable in the study of the neo-angiogenic process, characterized by an increase in vessel number, vascular permeability and flow into extra vascular spaces, better than direct measurement of the tumor or MVD count. Imaging will gain a role in monitoring targeted therapies, in the assessement of the evaluation of the antiangiogenic therapy and in the selection of patients eligible to be treated by this method. PEI in the tumor/PEI in the aorta and PS seem to be the most discriminative and predictive parameters. Others parameters (TTP, MSI, MSD) are operator and patient dependant. MTT is under evaluation as a good criterium of intersticial pressure around tumors No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 3548
CT perfusion as index of activity of antiangiogenic treatment of metastatic carcinoma
3548 Background: the aim of this study was to evaluate the different Computed Tomography (CT) parameters, characterizing tissue perfusion by contrast medium in metastatis to define their relation with activity of an antiangiogenic compound, targeting the VEGF receptors 1 and 2, using this qualitative and quantitative method. Methods: 113 patients with metastatic renal cell, pancreatic, colonic carcinoma and melanoma treated with antiangiogenic compound, were studied by dynamic CT (64 slices, GE) : calculation of time to peak (TTP), positive enhancement integral (PEI), maximum slope of increase (MSI), maximum slope of decrease (MSD), blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface (PS) were performed. Value distributions in the normal and neoplastic wall, their variation after antiangiogenic therapies and their relation to mono and bidimensionnal or volume measurement and pathological vessel density (MVD) were evaluated. Results: BF, TTP, and especially PEI and PS were highter in tumor than in normal liver, respectively in 68, 76, 100 and 100%; PS was > 20 ml/min/100g in 100% of patients. PEI and PS decrease in 78% and 82% of patients submitted to antiangiogenic treatment at the first course. Decreased tumor perfusion (TP) was observed in patients responding to therapy, including liver metastasis. Furthermore, in 40 out of 60 patients with stable or progressive disease by RECIST, decreased TP was strongly correlated with clinical improvement. Significant correlation between PEI in tumor/PEI in the aorta and PS was found (R=0,679). Conclusion: CT perfusion could be reliable in the study of the neo-angiogenic process, characterized by an increase in vessel number, vascular permeability and flow into extra vascular spaces, better than direct measurement of the tumor or MVD count. Imaging will gain a role in monitoring targeted therapies, in the assessement of the evaluation of the antiangiogenic therapy and in the selection of patients eligible to be treated by this method. PEI in the tumor/PEI in the aorta and PS seem to be the most discriminative and predictive parameters. Others parameters (TTP, MSI, MSD) are operator and patient dependant. MTT is under evaluation as a good criterium of intersticial pressure around tumors No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 22135
Serum HAAH level in NSCLC is a diagnostic and could be a predictive factor of clinical response
22135 Background: The human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins. It was recently reported that the serum HAAH level in lung cancer can facilitate an earlier diagnosis of lung cancer and increase the rate of survival (Specificity amongst smokers of 90% and sensitivity of 98%). In this study we firstly compared HAAH serum levels in NSCLC patients vs. healthy individuals. Subsequently a follow-up of this marker was made in order to understand the possible implication of this protein with clinical response to treatment. Methods: Using an experimental double monoclonal antibody sandwich ELISA, HAAH level was measured in the sera of 46 patients with non small cell lung cancer (NSCLC) in comparison to 15 healthy controls. A further follow-up of HAAH level was performed on 22 patients before and after the treatment. Results: Serum HAAH was detectable and variable in 92% of NSCLC patients (n=43). Serum HAAH was found to be undetectable in healthy donors. When patients were compared to healthy donors the pretreatment median level of serum HAAH was significantly higher in NSCLC patients (P=0.00059). HAAH level did not correlate with gender or age. At the end of the treatment a decrease of HAAH level was noted. When patients were classified according to the clinical response pre-treatment HAAH levels were higher in patients that had progressive disease despite treatment (n=19) as compared to responder (n=9) or stable disease patients (n=14). At the end of treatment, a decrease of serum HAAH level was noted specifically in responder patients. Conclusion: Our results suggest that determination of pre-treatment serum HAAH levels could be helpful in the stratification of patients according to their clinical response and their follow-up. Due to the small number of patients, these results must be considered preliminary and a study in a higher number of patients is ongoing in order to confirm these interesting results. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Panacea Pharmacceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 22135
Serum HAAH level in NSCLC is a diagnostic and could be a predictive factor of clinical response
22135 Background: The human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins. It was recently reported that the serum HAAH level in lung cancer can facilitate an earlier diagnosis of lung cancer and increase the rate of survival (Specificity amongst smokers of 90% and sensitivity of 98%). In this study we firstly compared HAAH serum levels in NSCLC patients vs. healthy individuals. Subsequently a follow-up of this marker was made in order to understand the possible implication of this protein with clinical response to treatment. Methods: Using an experimental double monoclonal antibody sandwich ELISA, HAAH level was measured in the sera of 46 patients with non small cell lung cancer (NSCLC) in comparison to 15 healthy controls. A further follow-up of HAAH level was performed on 22 patients before and after the treatment. Results: Serum HAAH was detectable and variable in 92% of NSCLC patients (n=43). Serum HAAH was found to be undetectable in healthy donors. When patients were compared to healthy donors the pretreatment median level of serum HAAH was significantly higher in NSCLC patients (P=0.00059). HAAH level did not correlate with gender or age. At the end of the treatment a decrease of HAAH level was noted. When patients were classified according to the clinical response pre-treatment HAAH levels were higher in patients that had progressive disease despite treatment (n=19) as compared to responder (n=9) or stable disease patients (n=14). At the end of treatment, a decrease of serum HAAH level was noted specifically in responder patients. Conclusion: Our results suggest that determination of pre-treatment serum HAAH levels could be helpful in the stratification of patients according to their clinical response and their follow-up. Due to the small number of patients, these results must be considered preliminary and a study in a higher number of patients is ongoing in order to confirm these interesting results. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Panacea Pharmacceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals Panacea Pharmaceuticals